Now showing items 10-29 of 84

      Calibrated response to emerging infections [1]
      Canada finally opens up data on new drugs and devices: Other regulators should take note of Health Canada’s substantive reforms [1]
      CDC tightens controls on scientists’ communication with news media [1]
      Challenges of independent assessment of potential harms of HPV vaccines [1]
      Cherry-picking by trialists and meta-analysts can drive conclusions about intervention efficacy [1]
      Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports [1]
      Clinical trial data: get them while you can [1]
      Contradictory findings on efficacy of neuraminidase inhibitors not cited [1]
      Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies [1]
      Convicting Zika [1]
      Correction: Integrating multiple data sources (MUDS) for meta-analysis to improve patient-centered outcomes research: A protocol [Syst Rev. 4, (2015) (143)] DOI: 10.1186/s13643-015-0134-z. [1]
      Covid-19 vaccine trial protocols released [1]
      Covid-19: Do many people have pre-existing immunity? [1]
      Covid-19: Should doctors recommend treatments and vaccines when full data are not publicly available? [1]
      Data too important to share: do those who control the data control the message? [1]
      Defining antibiotic effectiveness and resistance: how a private party may soon rule judgments over susceptibility testing [1]
      Determining the infectious potential of individuals with positive RT-PCR SARS-CoV-2 tests [1]
      Does oseltamivir really reduce complications of influenza? [1]
      EFPIA-PhRMA's principles for clinical trial data sharing have been misunderstood [1]
      The elusive definition of pandemic influenza [1]